Work

Randomized phase III trial of pemetrexed (Pem)+carboplatin (Cb)+bevacizumab (Bev) followed by maintenance Pem+Bev (Pem arm) versus paclitaxel (Pac)+Cb+Bev followed by maintenance Bev (Pac arm) in patients (pts) with stage IIIb/IV nonsquamous non-small cell lung cancer (nsNSCLC) (POINTBREAK): African American (AA) subset.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.e19150

Authors: Craig H. Reynolds, Jyoti D. Patel, Edward B. Garon, Mark R. Olsen, Philip D. Bonomi, Ramaswamy Govindan, Coleman K. Obasaju, Eduardo J. Pennella, Jingyi Liu, Susan C. Guba, David R. Spigel, Robert C. Hermann, Mark A. Socinski

Institutions: Northwestern University, University of California, Los Angeles, Rush University Medical Center, Washington University in St. Louis, Eli Lilly (United States), Tennessee Oncology, University of Pittsburgh Medical Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2595715428

Cites:

Cited by: 2

Related to: 10